What is Calidi Biotherapeutics Inc. (CLDI) stock price today?

Calidi Biotherapeutics Inc. (CLDI) currently trades at $0.22 per share. The stock has a market capitalization of $2.46M and a P/E ratio of —x.

Is CLDI stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Calidi Biotherapeutics Inc. has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is -16.57.

What is the CLDI stock price target for 2026?

WallStSmart's 12-month price target for Calidi Biotherapeutics Inc. is $0.29.

Is Calidi Biotherapeutics Inc. financially healthy?

Calidi Biotherapeutics Inc.'s Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of -16.57 places it in the distress.

CLDI

Calidi Biotherapeutics Inc.

NYSE MKT: CLDI · HEALTHCARE · BIOTECHNOLOGY

$0.22

+7.53% today

Updated 2026-04-30

Market cap

$2.46M

P/E ratio

—

P/S ratio

50.83x

EPS (TTM)

$-5.95

Dividend yield

—

52W range

$0 – $13

Volume

4.3M

Market cap

$2.46M

P/E ratio

—

P/S ratio

50.83x

EPS (TTM)

$-5.95

Dividend yield

—

52W range

$0 – $13

Volume

4.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-16.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$120.00

+53399.78%

12-Month target

$0.29

+29.29%

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.45x — low leverage

Risks

- Altman Z -16.57 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-5.07M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$45000.00	$0.00	$0.00	$0.00	$0.00
Net income	$-25.43M	$-29.22M	$-22.14M	$-19.91M	$-4.06M
EPS	—	—	—	—	$-5.95
Free cash flow	$-13.64M	$-27.57M	$-19.71M	$-21.41M	$-5.07M
Profit margin	-56,504.44%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CLDI	$2.46M	26	4.3	3.0	5.0	6.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Calidi Biotherapeutics Inc. trades at $0.22. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -16.57, it sits in the distress.

Frequently asked questions

What is Calidi Biotherapeutics Inc.'s stock price?

Calidi Biotherapeutics Inc. (CLDI) trades at $0.22.

Is Calidi Biotherapeutics Inc. overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Calidi Biotherapeutics Inc. (CLDI)?

The analyst target price is $120.00, representing +53399.8% upside from the current price of $0.22.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

-16.57 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

www.calidibio.com

Quick metrics

P/S ratio50.83x

ROE-701.00%

Beta1.42

50D MA$0.43

200D MA$1.96

Shares out0.01B

Float0.01B

Short ratio—

Avg volume4.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CLDI vs LLY →CLDI vs JNJ →CLDI vs ABBV →Stock screener →